What is the
OLYMPIA-4
clinical research study?

If you were diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), please know that you are not alone in your medical journey. B-cell lymphomas make up most of the non-Hodgkin lymphomas (NHL) globally.
Currently, we are working on developing potential treatments for B-NHL. OLYMPIA-4 is a phase 3 clinical research study that aims to evaluate the efficacy and safety of an investigational study treatment compared to standard of care (SOC) when given in combination with chemotherapy and autologous stem cell transplant (ASCT). This study is specifically for people whose cancer has stopped responding to treatment (also known as “refractory”) or has returned (also known as “relapsed”).
The treatment is called “investigational” because it has not been approved for use outside of this clinical study.

What are the study drugs?

    • Investigational treatment: The investigational treatment will be administered through an intravenous (IV) infusion (a needle in your arm). The investigational treatment is a bispecific antibody that works by activating your immune system’s T-cells and helping them target and kill cancerous cells.
    • Antibody treatment: The antibody treatment will be administered by IV infusion. The antibody treatment is part of the SOC for B-NHL along with chemotherapy. It is a monoclonal antibody. It sticks to the surface of a type of white blood cell called a “B-lymphocyte.” When this happens, the cell is killed by the immune system. You may or may not receive the antibody treatment according to the study doctor’s preference.
    • Chemotherapy treatment: Only one treatment group will receive chemotherapy. Chemotherapy will consist of 1 of 3 treatment regimens with or without the antibody treatment. Chemotherapy is administered by IV infusion along with an oral medication. Participants may also receive chemotherapy in preparation for an ASCT.
    • ASCT: An ASCT uses healthy blood stem cells from your own body to replace cells that were damaged by treatments, such as radiation or chemotherapy. ASCT may include inpatient admission.
In the study, participants will be randomly assigned to 1 of 2 treatment groups. If you qualify and choose to participate in OLYMPIA-4, you will have an equal (50%) chance of being assigned to either group. One group will receive the investigational treatment and the other will receive SOC (chemotherapy with or without an antibody treatment followed by ASCT). This study is “open label,” which means you will be told which treatment you are receiving.

What can I expect if I participate?

Study participation is 100% voluntary (your choice). You will receive information on what to expect, as well as your roles and responsibilities if you join the OLYMPIA-4 study. You may leave the study at any time without it affecting your regular health care.
If you join the study, there are certain things you will be expected to do. This includes attending study visits and undergoing certain assessments and procedures, such as imaging scans, biopsies and blood draws.
Participation in the study will include the screening period, treatment phase and the follow-up phase. During the screening period, several tests will be performed in order to ensure that you are eligible for OLYMPIA-4. Screening may last up to 28 days before the first day of the treatment period. The treatment phase will last about 6 months to 1 year with the duration and number of visits depending on which treatment group you participate in and your response to the treatment.
The follow-up period will consist of visits up to 6 times per year and continue until your condition worsens or reoccurs, you withdraw your consent or the study is over, whichever is earliest.
There will be no cost to you for the investigational treatments, visits, tests or supplies that are only required due to your participation in this study.  
Some of the medical care that you will be given during this study, such as ASCT, is the usual care a doctor would recommend for your condition even if you were not in the study. You or your health insurance will have to pay for this usual medical care, including SOC. You or your health insurance will also have to pay for medications, tests and supplies that are not required as part of the study. Your study doctor and study team are available to discuss this with you. 

What else should I know?

As with all treatments, there are possible risks when taking the investigational treatment. If you qualify and choose to participate, you will be provided with an Informed Consent Form that explains any possible risks and side effects. It is also possible that the study drugs may affect you in unknown ways. Your health and safety are our top priorities and will be closely monitored throughout your participation.

There is no guarantee that you will receive a medical benefit from participating in this study. Your condition may get better, stay the same or may even get worse. You are free to withdraw from the study for any reason and at any time.

Find a study site near you

To find out more about OLYMPIA-4 and whether it may be right for you, please contact your closest study site – they will be more than happy to help. Find your nearest study site
Site Finder

Am I Eligible?

If you wish to take part in the OLYMPIA-4 clinical research study, fill in the pre-screener questionnaire below to see if you may be eligible.
You may be eligible if you:
  • • Are ≥ 18 years of age or the legal age per country-specific regulations (for Singapore, the age requirement is ≥ 21 years old as per local regulation)
  • • Have refractory or relapsed B-NHL ≤ 12 months from the start of the initial treatment
  • • Are willing and able to attend study visits and undergo study-related procedures
  • • Are eligible for autologous stem cell transplant (ASCT)
There are other requirements to participate. A full medical check-up will be done to see if you can join this study. If you have other questions, share this website with your doctor to discuss this study.

Find a study site near you

If you have more questions about OLYMPIA-4, please contact the site closest to you by using our site finder tool.
Site Finder